Seven factors predict a delayed diagnosis of cardiac amyloidosis

Abstract Introduction: Diagnostic delay of cardiac amyloidosis (CAm) continues to challenge clinicians. We investigated features associated with delay and ascertained if a diagnostic delay had negative implications for the patient. Methods: We performed a retrospective chart review identifying 82 subjects with biopsy-proven and mass-spectrometry-identified CAm with clinical and epidemiologic data including first potential symptom of amyloidosis. Pathology slides were scored for extent of amyloid. Robust statistical analyses including generalized linear and ordered logistic regression analysis were performed. Results: There was a 22 month (median) delay in diagnosis, more pronounced (34 months) in subjects with transthyretin (ATTR) amyloidosis. Seven factors predict a delayed diagnosis including ATTR amyloid type (ratio =2.17, 95% CI 1.31–3.59), having carpal tunnel syndrome (2.13, CI 1.49–3.03) and age <70 at first symptom (1.85, CI 1.30–2.61). Individuals with delays of 1+ years had higher levels of NT proBNP (4451 vs. 2559 pg/mL, p = .016) and longer PR intervals (225 vs. 162 ms, p < .001) at the time of diagnosis. Conclusions: Diagnostic delays negatively affect cardiac function. Of the predictive clinical features, carpal tunnel syndrome was frequent and its presence should lead to a more aggressive analysis for CAm in the appropriate clinical settings.

[1]  E. Miller,et al.  Time Course of Common Clinical Manifestations in Patients with Transthyretin Cardiac Amyloidosis: Delay From Symptom Onset to Diagnosis. , 2018, Journal of cardiac failure.

[2]  B. Reyes,et al.  021 - Carpal Tunnel Syndrome and Amyloid Cardiomyopathy , 2017 .

[3]  A. Dispenzieri,et al.  Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response , 2017, Heart.

[4]  M. Gertz,et al.  Newer Therapies for Amyloid Cardiomyopathy , 2016, Current Heart Failure Reports.

[5]  James C Moon,et al.  Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis , 2016, Circulation.

[6]  P. Kellman,et al.  Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis , 2015, Circulation.

[7]  E. González-López,et al.  Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. , 2015, European heart journal.

[8]  R. Falk,et al.  Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. , 2015, Circulation. Heart failure.

[9]  Yang Zhang,et al.  Prognostic value of high-sensitivity cardiac troponin T in patients with endomyocardial-biopsy proven cardiac amyloidosis , 2014, Journal of geriatric cardiology : JGC.

[10]  J. Leipsic,et al.  Comparison of Al and Ttr Cardiac Amyloidosis: A Single Center Canadian Experience , 2013 .

[11]  M. Lo Monaco,et al.  TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients , 2013, Neurological Sciences.

[12]  M. Halushka,et al.  Relationship between monoclonal gammopathy and cardiac amyloid type. , 2013, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[13]  F. Salvi,et al.  Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. , 2013, European heart journal.

[14]  M. Lubberink,et al.  In Vivo Visualization of Amyloid Deposits in the Heart with 11C-PIB and PET , 2013, The Journal of Nuclear Medicine.

[15]  R. Falk,et al.  Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). , 2012, American heart journal.

[16]  D. Dingli,et al.  Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Falk,et al.  Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. , 2005, Archives of internal medicine.

[18]  M. Skinner,et al.  A rare transthyretin mutation (Asp18Glu) associated with cardiomyopathy , 2004, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[19]  T. Therneau,et al.  Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins , 2003, The Lancet.

[20]  J Ranstam,et al.  Prevalence of carpal tunnel syndrome in a general population. , 1999, JAMA.

[21]  R. Falk,et al.  Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. , 1997, Heart.

[22]  G. Merlini,et al.  Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium , 2015, Advances in Therapy.

[23]  E. Boerwinkle,et al.  The amyloidogenic V122I transthyretin variant in elderly black Americans. , 2015, The New England journal of medicine.